STE Q1 2026: Tariff Headwind Rises $15M as Healthcare and AST Margins Expand

2025-08-07 | By EarningsIQ Research

Starris (STE) delivered broad-based segment growth and margin expansion in Q1, but a $15 million tariff increase sharpened cost pressures even as foreign exchange provided a partial offset. The healthcare and AST businesses both posted double-digit order growth and backlog expansion, supporting management’s steady full-year outlook. Investors should watch for how shifting tariff regimes and healthcare utilization trends shape execution in the coming quarters.

Summary

• Tariff Escalation Outpaces Prior Guidance: Material increase in metal tariffs drives higher cost exposure for the remainder of the year.
• Healthcare and AST Segments Deliver Volume and Margin Gains: Order growth and backlog expansion in both units reinforce multi-segment momentum.
• Cash Flow and Dividend Prioritization Signal Capital Strength: Raised free cash flow outlook and continued dividend increases underscore balance sheet flexibility.

Performance Analysis

Starris posted 9% reported revenue growth and 8% constant currency organic growth in Q1, powered by volume and 230 basis points of price realization. Gross margin improved 20 basis points to 45.3%, as price and productivity outpaced inflation and tariff drag. Operating leverage and margin discipline contributed to a 50 basis point increase in operating margin, with net income from continuing operations reaching $231.2 million. Adjusted EPS rose 15% year-over-year, reflecting broad-based execution across the portfolio.

Segment performance was notably strong: Healthcare grew 8% organically, with capital equipment orders up 14% and backlog exceeding $400 million, while AST (Applied Sterilization Technologies, contract sterilization services) posted 10% organic growth and 12% service growth. Life Sciences saw 4% organic growth, led by an 8% gain in consumables and a 50%+ jump in capital equipment backlog. Free cash flow surged to $327 million, enabling continued debt paydown and a 10% dividend increase, marking the 20th consecutive annual dividend hike.

• Tariff Impact Intensifies: Increased tariffs on steel, aluminum, and copper, plus EU rate hikes, raised annual cost exposure by $15 million, primarily hitting the healthcare segment.
• Order Book Strengthens: Healthcare and Life Sciences capital equipment backlogs rose sharply, supporting forward visibility.
• Margin Expansion Sustained: Both AST and Life Sciences posted significant EBIT margin gains, aided by mix, pricing, and productivity.

While the top-line and margin trends remain positive, tariff escalation and higher employee healthcare utilization are emerging as new cost watchpoints. Management’s unchanged full-year guidance, despite a robust Q1, reflects prudent conservatism amid these evolving headwinds.

Executive Commentary

Strategic Positioning

1. Multi-Segment Growth with Order Book Depth

Healthcare and AST segments both delivered multi-pronged growth, with capital equipment and service revenues rising in tandem. Strong capital order intake and expanding backlogs in healthcare and life sciences signal sustained demand and forward visibility, supporting the company’s full-year revenue confidence.

2. Tariff and Cost Inflation Management

Tariff costs increased $15 million versus prior guidance, driven by higher US and EU metal tariffs. Management is offsetting this through price realization and productivity, but the rising cost base will pressure margins if inflation persists or price power wanes. Employee healthcare cost utilization also emerged as a new cost driver, with utilization—not premium hikes—fueling the increase.

3. Capital Allocation and Balance Sheet Discipline

With free cash flow guidance raised by $50 million to $820 million and gross debt to EBITDA at 1.2 times, Starris is positioned to pursue both M&A and shareholder returns. The company’s 20th consecutive dividend increase and ongoing share buybacks (mainly to offset dilution) reinforce a disciplined capital return philosophy, while management signals continued M&A appetite for both small and larger opportunities.

4. Regulatory and Competitive Positioning in Sterilization

Starris did not apply for recent US ethylene oxide sterilization regulatory relief, citing proactive facility upgrades and a newer asset base. This positioning may yield a competitive advantage as peers with older facilities face higher compliance costs or delay investments.

5. End-Market and Channel Trends

Healthcare procedure volumes and capital demand remain resilient, with no evidence of the softness or delays cited by some competitors. The ambulatory surgery center (ASC, outpatient surgical facilities) buildout continues to benefit Starris’s capital business, as facility shifts require new equipment and training solutions tailored to lower-scale environments.

Key Considerations

This quarter’s results highlight Starris’s ability to deliver consistent growth and margin expansion across segments, while navigating a more complex cost and regulatory landscape. The company’s proactive pricing, productivity, and capital allocation strategies are central to its resilience, but investors should monitor several evolving dynamics.

Key Considerations:

• Tariff Volatility: Recent metal tariff hikes (steel, aluminum, copper) and EU rate changes could pressure margins if not offset by pricing or productivity.
• Healthcare Utilization Risk: Higher employee health benefit utilization is driving incremental cost, a trend that may persist into 2026 for many companies.
• Order Backlog Strength: Record backlogs in healthcare and life sciences provide forward revenue visibility, but timing of capital shipments remains a variable.
• Regulatory Landscape: Starris’s newer sterilization facilities and proactive compliance investments may create a moat as regulatory scrutiny intensifies.
• M&A and Cash Deployment: With limited prepayable debt and rising cash, future capital allocation will hinge on the pace and scale of M&A opportunities.

Risks

Material risks include further escalation in tariffs or inflation, which could outpace pricing power and pressure margins. Healthcare utilization fluctuations, regulatory shifts, and delayed customer capital spending may also disrupt order conversion or segment growth. Management’s conservative guidance reflects these uncertainties, particularly in the context of evolving MedTech and pharma end markets.

Forward Outlook

For Q2 2026, Starris guided to:

• Constant currency organic revenue growth of 6% to 7% across all segments
• Flat EBIT margins at the high end of the earnings range

For full-year 2026, management maintained guidance:

• Adjusted earnings per share of $9.90 to $10.15, reflecting $45 million in tariff costs
• Free cash flow outlook raised to $820 million (+$50 million versus prior guidance)

Management highlighted several factors that will shape execution:

• Order backlog and service momentum underpin revenue visibility
• Tariff and healthcare cost inflation will be offset by price and currency tailwinds

Takeaways

Starris’s Q1 demonstrated multi-segment resilience and operational discipline, but rising tariffs and cost inflation will test the durability of margin gains in coming quarters.

• Segment Breadth Matters: Growth in healthcare, AST, and life sciences, with robust backlogs, diversifies revenue and reduces risk from single-market disruptions.
• Cost Headwinds Mount: Tariff and employee healthcare cost increases require continued pricing and productivity execution to sustain margin expansion.
• Capital Allocation Optionality: Rising cash and limited near-term debt maturities position Starris to pursue M&A or accelerate shareholder returns as opportunities arise.

Conclusion

Starris enters the remainder of 2026 with multi-segment momentum, order book strength, and expanded free cash flow guidance, but must navigate a more challenging cost environment. Prudent guidance and disciplined execution will be key to sustaining outperformance as tariff and inflation volatility persist.

Industry Read-Through

Starris’s experience with tariff escalation, healthcare cost inflation, and regulatory compliance offers a preview for other medtech and life sciences firms facing similar pressures. Order backlog growth and capital equipment demand suggest continued strength in hospital and life sciences capex, while the ASC buildout and regulatory shifts in sterilization highlight the need for asset modernization and compliance investment across the sector. Expect more companies to flag employee healthcare utilization and FX as key variables in upcoming quarters, with margin protection requiring active pricing and productivity management.

STE Healthcare Medical Devices Tariffs Capital Allocation Order Backlog Margin Expansion